The CEO's total reported compensation of $3,851,468 — composed of $965,655 base salary, $834,326 annual cash bonus (108% of target, tied to objective clinical, regulatory and commercial goals), and $2,007,000 in stock awards (RSUs vesting over four years) — reflects a reasonable pay mix for a small-cap biotechnology CEO, with approximately 75% of pay variable and at-risk, well above the 50-60% threshold the policy requires. The prior Say-on-Pay vote received 74% support, which exceeds the 70% threshold that would require evidence of responsive action, and the company has in fact made meaningful program enhancements including the introduction of performance stock awards (PSUs tied to 3-year relative total shareholder return vs. the Nasdaq Biotechnology Index), formal stock ownership guidelines, and an expanded clawback policy covering both cash and equity. Pay-for-performance alignment is adequate: variable pay is benchmarked at the median of a disclosed peer group of similarly-sized biopharma companies, the annual bonus is governed by pre-set objective criteria (not guaranteed), and the new PSU program introduces meaningful long-term performance conditions, so no policy trigger for a NO vote is met.

Non-audit fees of $2,120 represent less than 1% of audit fees of $991,300, far below the 50% threshold that would raise independence concerns; PwC has audited Vanda since the company commenced operations in 2003 (approximately 23 years), which is below the 25-year tenure threshold that would trigger a concern; and there are no disclosed material financial restatements attributable to audit failure, so all policy screens are passed.